Status:
COMPLETED
ED90 of Remimazolam Loading Dose for Sedation in Patients Under Monitored Anesthetic Care
Lead Sponsor:
Asan Medical Center
Conditions:
Remimazolam
Orthopedic Procedures
Eligibility:
All Genders
19-80 years
Phase:
PHASE4
Brief Summary
Currently used drugs for monitored general anesthesia include propofol, midazolam, and dexmedetomidine. Each drug has different advantages and disadvantages. Remimazolam causes a relatively small decr...
Eligibility Criteria
Inclusion
- ASA PS 1-3
- Patients who are scheduled to undergo upper/lower limb surgery under the monitored anesthetic care with remimazolam
Exclusion
- Patients who refuse to participate in this study
- Patients with hypersensitivity to benzodiazepine or flumazenil
- Patients with severe renal/hepatic disease
- Patients with drug/alcohol abuse
- Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically
- Patients with difficulty in communication
- Patients with severe obstructive sleep apnea or other airway problems
- Patients contraindicated to regional anesthesia
- Patients judged to be inappropriate for this study
Key Trial Info
Start Date :
April 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 2 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05340335
Start Date
April 18 2022
End Date
May 2 2022
Last Update
July 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 05505